Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) is getting mixed attention, but the stock is likely under pressure overall because of fresh regulatory and scientific setbacks tied to one of its key rare-disease drugs, Tavneos. At the same time, the shares have also benefited from broader investor interest and a recent strong run.

• Positive Sentiment: Amgen remains one of the most watched stocks on Zacks, and recent commentary notes the shares have had a strong multi-week and year-to-date run, suggesting continued investor interest and momentum. Article Title
• Neutral Sentiment: Viridian Therapeutics’ new FDA approval for Lumvoa is being viewed as a stronger competitor in thyroid eye disease, adding competitive pressure to Amgen’s Tepezza franchise rather than changing Amgen’s fundamentals directly. Article Title
• Negative Sentiment: The European Medicines Agency’s CHMP recommended revoking Tavneos’ marketing authorization in the EU, which raises the risk of lost international sales and creates a fresh regulatory overhang for Amgen. Article Title
• Negative Sentiment: The New England Journal of Medicine retracted the trial paper that supported Tavneos after FDA-related findings, increasing concerns about the reliability of the clinical data behind a drug that generated substantial revenue for Amgen. Article Title

Overall, Amgen (AMGN) looks like it is trading with a bearish bias today because investors are weighing the risk to Tavneos from both the EU revocation push and the journal retraction, even as the stock’s longer-term momentum and attention from traders provide some support.